AN2 Therapeutics prices $70M underwritten offering of 7.8M shares at $9.00

AN2 Therapeutics, Inc.

Underwritten offering of 7,777,778 shares at $9.00/share, gross proceeds ~$70M.
Investors include RA Capital, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital, Avidity Partners, Janus Henderson, Surveyor Capital.
Expected close on Aug 18, 2023; Cowen, Leerink, Evercore as book-runners.
Offering priced at premium to closing price; sold under effective shelf registration statement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AN2 Therapeutics, Inc. entered into Underwriting Agreement with Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named in Schedule A therein valued at approximately $70.0 million (effective 2023-08-15).

Action: entry
Agreement: underwriting
Counterparty: Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named in Schedule A therein
Value: approximately $70.0 million
Effective: 2023-08-15

Exact text from the filing

On August 15, 2023, AN2 Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named in Schedule A therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of 7,777,778 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $9.00 per share.

View on SEC.gov

147 material agreements filed in the last 30 days. Browse all material agreements →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-214362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.